Murine RANK-human immunoglobulin fusion protein

Drug Profile

Murine RANK-human immunoglobulin fusion protein

Alternative Names: gkB-IgG Fc fusion protein; muRANK.Fc

Latest Information Update: 10 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; University of Texas Health Science Center at San Antonio
  • Class Immunoglobulin fusion proteins
  • Mechanism of Action Osteoclast inhibitors; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant hypercalcaemia

Most Recent Events

  • 10 Sep 2008 Discontinued - Preclinical for Malignant hypercalcaemia in USA (Parenteral)
  • 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
  • 26 Jun 2001 Preclinical development for Malignant hypercalcaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top